Skip to main content
. 2020 Mar 17;2(1):97–109. doi: 10.1016/j.jaccao.2020.02.011

Figure 3.

Figure 3

Management of CRS

Low-grade cytokine release syndrome (CRS) can be managed with supportive care alone. Tocilizumab, an interleukin (IL)-6 receptor blocker, is considered as a first line of treatment in patients with grade 2 or higher CRS. When this approach is ineffective, a dose of corticosteroids is the second-line treatment. ASTCT = American Society for Transplantation and Cellular Therapy.